Ngaba i-Depo Provera Icebo?

Nangona ukuphumelela kwayo, ukulawulwa kokuzalwa kubangela ukukhathazeka

UDepo Provera (i-depot medroxyprogesterone acetate) isistim se-hormonal esisetyenziswe njengendlela eguquguqukayo yokulawula ukuzalwa . Nangona ukuba le nkunkuma ingama-99.7 ekhulwini okusebenzayo ekukhuseleni ukukhulelwa kwiiveki ezi-14, ukufumana ubunzima ngokuphindaphindiweyo kubangelwa isizathu sokuba kutheni abesifazane bayeke ukusebenzisa iDepo Provera.

Indlela iDepo Provera isebenza ngayo

UDepo Provera iqulethe uhlobo lweprogesterone olubizwa ngokuba yiprogesin .

Yifomu ejoyiweyo yesicatshulwa esifanayo, esaziwa njengePravera, esetyenziselwa ukunyanga iingxaki zokuya esikhathini ezibangelwa ukungalingani kwe-hormone.

Ulwaphulo olusisiseko lwe-progesin luvimbela u-ovulation ukuba lube khona. Kananjalo lukhupha i-mucus yomlomo eyenza kube nzima ukuba isidoda sidlule kwisibeleko somlomo. Ngaphezu koko, isenzo se-hormonal senza utyumba lwezilwanyana ze-uterine, okwenza kube nzima ukuba iqanda elikhulelweyo lifakela ukususela kuba akukho izicubu ezaneleyo eludongeni lwe-uterine ukuze lufumane.

UDepo Provera unemiphumo emibi yezona ziphumo, eziqhelekileyo zazo ziquka:

Iziganeko ezininzi, ezibi kakhulu ziyaziwa ukuba zenzeke ziquka umngcipheko okhulayo wokuba neziphene zokuzalwa xa zithathwa xa zikhulelwe kunye nokulahleka kwethambo lomnwabiwo-mhlaba (imeko eguqulelwe ngokutsha xa unyango lugqityiwe).

Kodwa, ngokuthakazelisayo ngokwaneleyo, umphumo omnye wecala oza kubangela ukuba uxinzelelo olukhulu phakathi kwabasebenzisi luyingozi yokufumana ubunzima.

I-Depo Provera kunye noGawulayo

Ukususela ngo-2009, uphando luye lwaqinisekisa ukuba iDepo Provera inokubangela ukuba abafazi bafumane ubunzima. Kodwa isiqingatha salo mphumo, nangona kunjalo, sinokuhluka ngokubalulekayo kunye nokufaka ezinye iipounds ezimbalwa ngelixa ezinye zongeza okanye iingubo ezimbini zokugqoka.

Enye yezifundo ezibanzi, ezenziwa ngabaphandi kwi-Yunivesithi yaseTexas Medical Branch eGalveston, xa kuthelekiswa nokuzuza ubunzima kwabasetyhini abangama-703 abasebenzisa iipilisi , i-Depo Provera, okanye i-non-hormonal contraception (njenge- diaphragm , IUD , okanye i- sponge ).

Abathathi-nxaxheba babebandakanya ama-200 ase-Afrika aseMerika, ama-247 abamhlophe, kunye nama-245 aseApanishi.

Oko abaphandi abakufumene kukuba iDepo Provera ayizange idale ukufumana ubunzima ngaphezu kwexesha leenyanga ezingama-36, kwenzelwa oko ngokunyusa amaninzi omzimba. Ukuzuza ubuninzi phakathi kwabasebenzisi bepilisi, ngokuchaseneyo, bekujoliswe ngokukodwa ngokugcinwa kwamanzi. Konke kuxelelwe, abafazi abasebenzisa i-Depo Provera inzuzo ezuzekileyo kwi:

Iqondo lokuzuza ubunzima libonakala lihambelana ngqo nomlinganiselo weDepo Provera osetyenziswayo. Ukongezelela, abesetyhini abangapheliyo babonakala bengozi kakhulu kule mpahla ngamaphesenti angama-50 ukuba banokugqithisa emva kweminyaka emithathu.

Ngethamsanqa, esi siphumo sibonakala siphendulwa ngokukodwa phakathi kwabasetyhini abaye bavala uDepo Provera kwaye batshintshela kwi-contrahortive ye-nonhormonal. Kwala mabhinqa, kwakukho ukulahleka kwesisindo esi-3.75 iipounds emva kweenyanga ezingama-24.

Kwiphepha le-flip, abo batshintshela kwipilisi bafumana inzuzo yee-3.75 iipounds emva kweenyanga ezingama-24 (kwakhona, ngaphezulu ngenxa yokugcinwa kwamanzi ngaphezu kokuqokelela kwamanqatha).

ILizwi

Olu khetho lokuqhawula imithi luyodwa. Kwababhinqa abathile, iinzuzo zokulungelelanisa zingaba zikhulu kakhulu naziphi na iziphumo ezichaphazelekayo.

Ekupheleni, akukho mpendulo echanekileyo okanye engalunganga.

Ukuba ukhetha ukusebenzisa i-Depo Provera, kunokwenzeka ukunciphisa umngcipheko wakho ngokutya okufanelekileyo kunye nokuzivocavoca rhoqo. Buza ugqirha wakho ukuba uthunyelwe kwisondlo esithile esikhethekileyo esingakwazi ukunika iingcebiso malunga nendlela yokugcina isisindo sakho esilungileyo ngokukhulisa imetabolism yakho ngemisebenzi kunye nokulawula ukutya kwakho kwe-caloric kunye ne-fat.

> Umthombo:

> Berenson, A. kunye noR Rahman, M. "Utshintsho lwesisindo, i-fat total, i-percent fat fat, kunye ne-central-to-peripheral ratio ratio echaphazelekayo kunye nokusetyenziswa komlomo. I-American Journal ye-Obstetrics ne-Gynecology . 2009; 220 (3): 329 e1-329 e8.